Article

MP77-15 A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL ASSESSING WHETHER MRI-TARGETED BIOPSY IS NON-INFERIOR TO STANDARD TRANS-RECTAL ULTRASOUND GUIDED BIOPSY FOR THE DIAGNOSIS OF CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITHOUT PRIOR BIOPSY - THE PRECISION STUDY: PROSTATE EVALUATION FOR CLINICALLY IMPORTANT DISEASE, SAMPLING USING IMAGE-GUIDANCE OR NOT? (NCT02380027)

Authors:
Veeru Kasivisvanathan at University College London
Veeru Kasivisvanathan
Antti Rannikko at Helsinki University Central Hospital
Antti Rannikko
Marcelo Borghi
Marcelo Borghi
Marcelo Borghi
  • This person is not on ResearchGate, or hasn't claimed this research yet.
Valeria Panebianco at Sapienza University of Rome
Valeria Panebianco
Show all 40 authorsHide
Download citation
To read the full-text of this research, you can request a copy directly from the authors.

No full-text available

Request Full-text Paper PDF

To read the full-text of this research,
you can request a copy directly from the authors.

... According to our findings, patients diagnosed prostate cancer have shown remarkably higher serum PSA (19), and fee-to-total PSA levels (20), prostate volume (21) and also PSA density (21). Although the remarkable higher levels of mentioned factors among the cancerous people in comparison to BPH are in line with the previous studies (20,21), to definite cancer diagnosis, trans-rectal biopsies were also required (22). ...
Evaluation of the urine mRNA-PCA3 expression level in prostate patients; comparison between benign prostatic hyperplasia and cancer
Article
Full-text available
  • Feb 2022
Introduction: Prostate cancer is among the most common malignancies in men which can be well-managed if early diagnosed. Nevertheless, to date, no accurate index has been detected in order to differentiate prostate cancer from the other benign conditions practically except biopsies that is an invasive procedure. Objectives: The current study is aimed to assess the values of urinary prostate cancer antigen 3 (PCA3) in prostate cancer diagnosis. Patients and Methods: This case-control study was conducted on 28 patients with elevated levels of prostate-specific antigen (PSA) who underwent transrectal prostate biopsies in 2019. The urinary level of PCA 3 was measured using real-time polymerase chain reaction (RT-PCR). Ultrasonography was performed to assess the volume of prostate, as well. PSA density (PSAD) was defined as PSA divided by prostate volume. The patients were divided into two groups of benign prostatic hyperplasia (BPH) or prostate cancer based on prostate biopsy pathological report. The values of PCA 3 were evaluated. Results: PCA 3 had accuracy of 0.708 at cut-off point of 27.75 with measured AUC of 0.720 (95% CI: 0.510- 0.931), sensitivity and specificity of 72% and 69%, respectively. PSA had accuracy, sensitivity, and specificity of 0.708, 70% and 71.4% at cut-off of 9, whereas PSAD had 0.667, 88% and 50% at cut-off of 4.8, respectively. Conclusion: Based on the findings of this study, urinary PCA 3 can be considered as a valuable biomarker for the prediction of malignancy in prostate biopsies with the sensitivity and specificity of 72.7% and 69.2% at the cut-off level of 27.75, respectively.
View
ResearchGate has not been able to resolve any references for this publication.